Peyer James

SEC source: 0001567619-22-001007 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,929,413

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-000008 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,919,413

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-022649 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,918,286

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.75 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-022593 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,849,286

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-022540 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,837,998

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-022520 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,834,286

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.20 to $5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-022392 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,823,286

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.25 to $5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-022339 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,823,169

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.23 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-009211 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,812,244

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-008410 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,811,894

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.75 to $13.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-008359 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,811,509

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.00 to $13.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-008047 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,809,544

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-007835 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,807,544

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-007469 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,805,544

F1 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-007281 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,804,544

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.99 to $12.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-006934 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,802,544

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.00 to $14.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-006867 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,798,794

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.00 to $14.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-008804 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,798,293

F1 · shares: This Form 4 is being amended to correct the number of shares purchased. The original Form 4 filed on March 24, 2021, overstated the number of shares purchased.

F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.00 to $14.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F3 · ownership.direct: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F3 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-006778 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,788,794

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.00 to $15.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-006681 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,786,611

F1 · ownership.direct: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-006035 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,785,794

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.20 to $15.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-005823 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,784,794

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.50 to $14.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-005716 · doc1.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,776,794

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.00 to $14.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-005716 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,774,794

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.75 to $16.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-21-005574 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,771,794

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.00 to $16.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian BioPharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-21-015883 · doc4.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,768,794

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.75 to $16.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-21-014686 · doc4.xml · nonDerivative · entry 3

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,763,794

F4 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.59 to $16.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-21-014686 · doc4.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,751,794

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.95 to $18.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-21-014686 · doc4.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,750,894

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.43 to $17.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-21-014429 · doc4.xml · nonDerivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,732,794

F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.70 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-21-014429 · doc4.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,718,494

F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.65 to $17.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-21-014048 · doc4.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,712,494

F1 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $18.55 to $19.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of the Cambrian Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of the Cambrian Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-21-013165 · doc4.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,702,692

F1 · price: The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $19.50 to $19.8999, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set herein.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F2 · ownership.nature: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-21-012342 · doc4.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,690,906

F1 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.nature: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001567619-22-008802 · doc1.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,690,905

F2 · shares: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F1 · ownership.direct: This Form 4 is being amended to correct the number of shares purchased. The original Form 4 filed on February 19, 2021, overstated the number of shares purchased.

F1 · ownership.nature: This Form 4 is being amended to correct the number of shares purchased. The original Form 4 filed on February 19, 2021, overstated the number of shares purchased.

SEC source: 0001209191-21-009413 · doc4.xml · derivative · entry 3

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock · 100,458 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date.

F2 · derivative.exercise_date: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date.

F2 · derivative.expiration_date: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date.

F3 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F3 · ownership.nature: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-21-009413 · doc4.xml · derivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,306,870 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date.

F2 · derivative.exercise_date: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date.

F2 · derivative.expiration_date: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date.

F3 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F3 · ownership.nature: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-21-009413 · doc4.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,690,153

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The total represents shares received upon conversion of shares of Series AA Preferred Stock and Series BB Preferred Stock.

F2 · price: Each share of the Series AA Preferred Stock and Series BB Preferred Stock converted to 0.0208333 shares of the Issuer's common stock, effective immediately prior to the closing of the Issuer's initial public offering of its common stock. The Series AA Preferred Stock and Series BB Preferred Stock haves no expiration date.

F3 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

F3 · ownership.nature: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian").The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-21-008092 · doc4.xml · derivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 16,666

Underlying: Common Stock · 16,666 shares

Expires 2031-02-02

F1 · derivative.exercise_date: One thirty-sixth (1/36th) of the options granted shall vest and become exercisable each month following February 3, 2021, the Vesting Commencement Date, over three years such that the options shall be 100% vested on the third anniversary of the Vesting Commencement Date, subject to Continuous Service (as defined in the 2021 Equity Incentive Plan) of James Peyer on the Issuer's Board of Directors, through each such vesting date. Mr. Peyer is the Chief Executive Officer of Cambrian and disclaims beneficial ownership of such shares.

F2 · ownership.nature: These options are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Dr. Peyer disclaims beneficial ownership of such shares.